test

Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)(CALGB 80802)

Conditions

Liver

What is the purpose of this trial?

Primary - Compare overall survival (OS) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib. Secondary - Compare time to progression (TTP) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib; compare progression-free-survival (PFS) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib; compare tumor response using RECIST criteria of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib.

Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
CALGB
Dates:
05/07/2014
Last Updated:
Study HIC#:
1107008793